Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

SIB-1508Y associated with improvement in cognitive deficits in Parkinson's model

March 17, 1997

Repeated IVIg for relapsing-remitting MS

March 17, 1997

First approval for Zomig; antimigraine agents in development

March 14, 1997

Substance P antagonists described by Pfizer

March 14, 1997

Knoll claims two series of compounds for CNS disorders

March 14, 1997

Akzo Nobel reveals new dopamine antagonists

March 14, 1997

NMDA antagonists claimed by Novartis

March 14, 1997

Antiparkinson Rx from Sumitomo in pivotal European trials

March 13, 1997

Somatostatin receptor antagonists prepared by Novartis

March 13, 1997

First approval for naratriptan

March 12, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...